ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "messenger RNA (mRNA)"

  • Abstract Number: 019 • 2020 Pediatric Rheumatology Symposium

    Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

    Mingce Zhang 1, Remy Cron 1, Devin Absher 2, Prescott Atkinson 1, W. Winn Chatham 1 and Randy Cron1, 1University of Alabama at Birmingham, Birmingham, 2HudsonAlpha Institute for Biotechnology, Huntsville

    Background/Purpose: Cytokine storm syndromes (CSS), such as macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (HLH), are life threatening conditions that commonly present with unremitting…
  • Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting

    Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

    Angela R Jones-Leone1, Shaun Flint 2, Roger Abramino Levy 3, David Roth 4, Robert Henderson 2, Christel Wilkinson 2, Beulah Ji 5 and Damon L Bass 3, 1GlaxoSmithKline, Upper Providence, 2GlaxoSmithKline, Stevenage, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4GSK, Collegeville, PA, 5GSK, Uxbridge, Middlesex, United Kingdom

    Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…
  • Abstract Number: 2656 • 2017 ACR/ARHP Annual Meeting

    Alterations of the Splicing Machinery Components in Leukocytes from Systemic Lupus Erythematosus Patients Influences Its Development and Atherothrombotic Profile and Drives the Therapeutic Response

    Carlos Perez-Sanchez1, Maria Ángeles Aguirre Zamorano1, Sergio Pedraza-Arévalo2, Mercedes del Río-Moreno2, Irene Cecchi3, Patricia Ruiz-Limon4, Nuria Barbarroja1, Yolanda Jiménez-Gómez1, Ivan Arias de la Rosa4, Maria Carmen Abalos-Aguilera4, Pedro Segui5, Eduardo Collantes-Estévez1, Justo P Castaño2, Raul M Luque6, Maria Jose Cuadrado7 and Chary Lopez-Pedrera1, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Department of Cell Biology, Physiology and Immunology. University of Cordoba, Reina Sofia Hospital, IMIBIC, CIBERobn, and ceiA3, Córdoba, Spain, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 4Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6Department of Cell Biology, Physiology and Immunology. University of Cordoba, Hospital Universitario Reina Sofia (HURS), Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBERobn, and ceiA3, Córdoba, Spain, 7St Thomas Hospital, Lupus Research Unit, London, United Kingdom

    Background/Purpose: Recent studies emphasize the relevance of alternative splicing in the development of genetic and autoimmune diseases. The aim of this study was to identify…
  • Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting

    Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

    Philip Brohawn1, Lingning Santiago2, Chris Morehouse1, Brandon Higgs1, Gabor Illei1 and Koustubh Ranade1, 1MedImmune, Gaithersburg, MD, 2MedImmune, Mountain View, CA

    Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences